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INTRODUCTION
Providencia species are members of the Enterobacteriace-
ae and an uncommon cause of infections, unlike many 
other bacteria in this family. Among the species in this 
genus, Providencia stuartii and Providencia rettgeri are the 
most common causes of infections, especially urinary 
tract infections (UTIs), in hospitalized patients or nurs-
ing care facilities [1,2]. However, Providencia bacteremia 
is uncommon and few studies on the subject have been 
published [3-5]. Although the prevalence of Providencia 
bacteremia is low, proper empirical antibiotic therapy is 
important because Providencia species are often resistant 
to multiple antibiotics [6]. 
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Background/Aims: Providencia species frequently colonize urinary catheters and 
cause urinary tract infections (UTIs); however, bacteremia is uncommon and not 
well understood. We investigated the clinical features of Providencia bacteremia 
and the antibiotic susceptibility of Providencia species. 
Methods: We identified cases of Providencia bacteremia from May 2001 to April 
2013 at a tertiary care hospital. The medical records of pertinent patients were re-
viewed. 
Results: Fourteen cases of Providencia bacteremia occurred; the incidence rate was 
0.41 per 10,000 admissions. The median age of the patients was 64.5 years. Eleven 
cases (78.6%) were nosocomial infections and nine cases (64.3%) were polymicro-
bial bacteremia. The most common underlying conditions were cerebrovascular/
neurologic disease (n = 10) and an indwelling urinary catheter (n = 10, 71.4%). A 
UTI was the most common source of bacteremia (n = 5, 35.7%). The overall mor-
tality rate was 29% (n = 4); in each case, death occurred within 4 days of the onset 
of bacteremia. Primary bacteremia was more fatal than other types of bacteremia 
(mortality rate, 75% [3/4] vs. 10% [1/10], p = 0.041). The underlying disease severity, 
Acute Physiologic and Chronic Health Evaluation II scores, and Pitt bacteremia 
scores were significantly higher in nonsurvivors ( p = 0.016, p =0.004, and p = 0.002, 
respectively). Susceptibility to cefepime, imipenem, and piperacillin/tazobactam 
was noted in 100%, 86%, and 86% of the isolates, respectively. 
Conclusions: Providencia bacteremia occurred frequently in elderly patients with 
cerebrovascular or neurologic disease. Although Providencia bacteremia is uncom-
mon, it can be rapidly fatal and polymicrobial. These characteristics suggest that 
the selection of appropriate antibiotic therapy could be complicated in Providencia 
bacteremia. 
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The purpose of this study was to investigate the clin-
ical features, outcome of patients with Providencia bac-
teremia, and antibiotic susceptibility of Providencia spe-
cies. 
METHODS
Study design and patients
This cross-sectional study was conducted at a tertiary 
care university hospital in Wonju, Korea. Microbiology 
laboratory records were obtained for the period starting 
in May 2001 and ending in April 2013. Patients whose 
blood cultures grew Providencia species were identified 
and pertinent medical records were retrospectively re-
viewed. This study was approved by our Institutional 
Review Board (YWMR-13-05-037). 
Identification and antimicrobial susceptibility testing 
Identification and antimicrobial susceptibility testing 
for Providencia species were performed using the mi-
croplate method, VITEK 2 system (BioMérieux, Marcy 
l’Étoile, France), or MicroScan WalkAway System (Sie-
mens Healthcare Diagnostics, Sacramento, CA, USA). 
The results were interpreted according to Clinical and 
Laboratory Standards Institute guidelines [7]. Interme-
diate susceptibility to antibiotics was considered to be 
drug resistance. 
Definitions 
Providencia bacteremia was defined as the isolation of 
Providencia species from one or more blood culture sets 
in a patient having two or more systemic inflammatory 
response syndrome criteria [8]. All positive blood cul-
tures taken within a 72-hour period were considered to 
represent the same episode. Nosocomial bloodstream 
infection was defined as a positive blood culture ob-
tained 48 hours after admission with no evidence of 
infection at the time of admission, or if the infection 
was acquired at another hospital before transfer to the 
study hospital. Polymicrobial bacteremia was defined 
as more than one organism isolated from blood culture 
sets during one episode of bacteremia. The severity of 
underlying disease was classified into three categories 
according to the criteria of McCabe and Jackson [9]: 
rapidly fatal, ultimately fatal, and nonfatal. The severi-
ty of illness at the onset of bacteremia was assessed by 
the Pitt bacteremia score [10] and the Acute Physiologic 
and Chronic Health Evaluation (APACHE) II score. The 
source of bacteremia was determined on the basis of 
clinical data and a culture result that was positive for 
the same organisms. Primary bacteremia was defined as 
bacteremia without an apparent focus or portal of entry. 
Empiric antibiotic therapy was considered to be appro-
priate when at least one effective drug was included in 
the empirical regimen and the dose and pattern of ad-
ministration were in accordance with current medical 
standards. 
Statistical analysis
The descriptive analysis consisted of the absolute num-
ber (percentage) or median (range) for various parameters. 
Continuous variables were compared by the Mann-Whit-
ney U test. Fisher exact test or the chi-square test was 
used to test whether differences existed between groups 
for categorical variables. For all analyses, p < 0.05 was con-
sidered to be statistically significant. All statistical analy-
ses were performed using IBM SPSS version 20 (IBM Co., 
Armonk, NY, USA).
RESULTS
During the 13-year study period, 14 cases of Providencia 
bacteremia occurred. None of the patients had recurrent 
bacteremia. The incidence rate was 0.41 per 10,000 ad-
missions. The occurrence of Providencia bacteremia was 
sporadic and showed no evidence of an outbreak during 
the study period.
The demographic data and clinical characteristics of 
the patients are shown in Table 1. Ten of the patients 
(71.4%) were male. The median patient age was 64.5 years 
(range, 7 to 78). Seven patients (50%) were older than 65. 
Eleven cases (78.6%) were nosocomial infections, and 
only one patient developed bacteremia in the inten-
sive care unit. One or more underlying conditions were 
present in 13 patients (93%): rapidly fatal (three patients), 
ultimately fatal (eight patients), and nonfatal (two pa-
tients). Cerebrovascular or neurological disease was the 
most common underlying disease (71.4%), followed by 
urologic disease (42.9%). Urinary catheters had been in-
serted in 10 patients (71.4%).
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Table 1. Demographic and clinical characteristics of patients with Providencia bacteremia
Characteristic
All 
(n = 14)
Survivors 
(n = 10)
Non-survivors 
(n = 4)
p value
Sex (male) 10  7 3 1.0
Age, yr 64.5 (7–78) 64.5 (7–78)    67 (41 –78) 0.733
Nosocomial acquisition  11  8 3 1.0
Acquisition at intensive care unit 1  1 0 1.0
McCabe and Jackson’s classification   0.016a
   Rapidly fatal  3 0 3
   Ultimately fatal  8  7 1
   Nonfatal  2  2 0
   No underlying condition 1  1 0
Underlying conditions
   Malignancy  2 0 2 0.066
   Recent chemotherapy/immunosuppression  2 0 2 0.066
   Cerebrovascular/neurological dysfunction 10  8 2  0.520
   Diabetes mellitus  3 3 0  0.505
   Chronic respiratory disease   3 1 2  0.176
   Chronic kidney disease 1 1 0 1.0
   Liver cirrhosis 1 0 1  0.286
   Heart failure   3 2 1 1.0
   Hematologic disease 0 0 0 -
   Urologic disease   6 4 2 1.0
Indwelling urinary catheter 10 6   4  0.251
Polymicrobial infection   9 7 2  0.580
Species of Providencia
   P. stuartii   5 3 2 0.58
   P. rettgeri 7 5 2 1.0
   P. alcalifaciens 1 1 0 1.0
   Unidentified 1 1 0 1.0
Source of bacteremia 
   Primary bacteremia   4 1 3  0.041
   Urinary tract infection   5 4 1 1.0
   Pneumonia/empyema   3 3 0  0.505
   Catheter associated infection 1 1 0 1.0
   Gastroenteritis 1 1 0 1.0
Appropriateness of initial empirical antibiotic therapy   8 6 2 1.0
APACHE II score 15.5 (3–27)  8.5 (3–22)    24 (21–27)  0.004
Pitt bacteremia score 2.5 (0–9)   1 (0–5)   8 (6–9)  0.002
Complications 
   Septic shock 7 3   4  0.07
   Adult respiratory distress syndrome 3 0 3  0.011
   Acute kidney injury 3 1 2  0.176
   Mental change 5 1  4  0.005
   Intensive care unit  admission 5 2 3  0.095
Values are presented as number or median (range).
APACHE II, Acute Physiologic and Chronic Health Evaluation II.
aValue by Linear by linear association.
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There were nine cases (64.3%) of polymicrobial bac-
teremia. In seven of these cases, only one other bacte-
rium was isolated with Providencia: Escherichia coli (two 
patients), Streptococcus agalactiae (one patient), Pseudomo-
nas aeruginosa (one patient), Enterococcus (one patient), 
viridans group streptococci (one patient), and Proteus 
mirabilis (one patient). Two additional organisms were 
isolated with Providencia in two patients: E. coli and En-
terococcus (source of bacteremia: gastroenteritis), and P. 
aeruginosa and Burkholderia cepacia (source of bacteremia: 
central venous catheter). The most frequently isolated 
co-pathogen was E. coli (3/9, 33.3%). P. rettgeri was the 
most common species (n = 7, 50%), followed by P. stu-
artii (n = 5, 35.7%). The antimicrobial susceptibility test-
ing results are shown in Table 2. The Providencia species 
in this study showed resistance to tobramycin but were 
susceptible to amikacin and isepamicin. Susceptibility 
to ciprofloxacin was only seen in 50% of the isolates. 
More than 80% of the isolated strains were susceptible 
to cefepime, imipenem, and piperacillin/tazobactam. 
The most frequently prescribed empirical antimicrobial 
was cefoperazone/sulbactam (seven patients); 70% of the 
isolated Providencia species were susceptible to cefoper-
azone/sulbactam.
The most common source of bacteremia was a UTI, 
followed by unknown sources. P. rettgeri was the most 
frequently isolated species in patients with a UTI or pri-
mary bacteremia (3/5 and 3/4, respectively). In contrast, 
2/3 of pneumonia cases were due to P. stuartii. In one 
case of gastroenteritis, P. rettgeri was the responsible 
pathogen.
The overall in-hospital mortality was 28.6% (4/14). All 
of the nonsurvivors had rapidly fatal or ultimately fa-
tal underlying conditions, and the underlying illness 
severity was significantly higher in nonsurvivors (p = 
0.016). The most common underlying conditions were 
malignancy, recent chemotherapy or immunosuppres-
sive therapy, cerebrovascular or neurological dysfunc-
tion, and urologic disease. All of the nonsurvivors had 
indwelling urinary catheters. Among the nonsurvivors, 
50% had polymicrobial bacteremia. A fatal outcome was 
more common in patients with primary bacteremia 
than in those with other types of bacteremia (3/4 vs. 1/10, 
p = 0.041). All four of these patients died before antibiotic 
susceptibility results were available; three patients died 
within 48 hours and one patient died 4 days after the 
onset of bacteremia. Eight patients (57.1%) received ap-
propriate empirical antibiotic therapy, while six did not. 
The appropriateness of the initial empirical antibiotic 
regimen was similar between the survivors and nonsur-
vivors. Since all of the nonsurvivors died within 4 days, 
we could not evaluate the appropriateness of the defini-
tive therapy. The APACHE II and Pitt bacteremia scores 
on the day of blood culture were significantly higher in 
the nonsurvivors (p = 0.004 and p = 0.002, respectively). 
Complications such as septic shock, respiratory failure, 
and mental change developed more frequently in non-
survivors (Table 1). 
DISCUSSION
The genus Providencia of the family Enterobacteriaceae 
consists of five species: P. alcalifaciens, P. heimbachae, P. 
rettgeri, P. rustigianii, and P. stuartii. Among them, P. stu-
artii and P. rettgeri are most commonly associated with 
UTIs. They frequently colonize indwelling urinary cath-
eters in nursing home residents and can cause hospital 
outbreaks [1]. However, Providencia bacteremia is un-
common. In a review by Woods and Watanakunakorn 
Table 2. In vitro susceptibilities of Providencia isolates
Antibiotics 
 No. of susceptible/
tested
Cephalothin 1/13
Trimethoprim/sulfamethoxazole  6/14
Ciprofloxacin 7/14
Amikacin  12/14
Gentamicin 10/14
Tobramycin 7/14
Cefoperazone/sulbactam 7/10
Aztreonam 11/14
Imipenem 12/14
Cefotaxime 7/14
Cefamandole 7/10
Ampicillin 6/14
Cefta zidime 9/14
Isepamicin 9/10
Piperacillin/tazobactam 12/14
Cefepime 14/14
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[4], the incidence of P. stuartii bacteremia was 0.17 per 
1,000 admissions during a 12-year period. In a review 
by Kim et al. [5], the incidence of Providencia bactere-
mia was 0.16 per 10,000 admissions over a decade. Our 
study confirms that Providencia bacteremia is uncom-
mon; however, the incidence rate in our study was three 
times higher than that in the review of Kim et al. [5], and 
four times lower than that in the review of Woods and 
Watanakunakorn [4]. Providencia species are ubiquitous 
and can be isolated from urine, the throat, perineum, 
axilla, stool, blood, and wounds in humans [1]. Among 
these specimen types, Providencia are most frequent-
ly isolated from the urine of elderly patients with uri-
nary catheters. The reasons for the variable incidence of 
Providencia bacteremia are not apparent, but the types of 
patient and institution might contribute to such a dif-
ference. For example, the proportion of elderly patients 
in our hospital is higher than that in other urban areas 
in Korea.
Except for one study [5], the urinary tract was the most 
common source of Providencia bacteremia in previous 
studies (71% and 100%, respectively) [3,4]. In this study, 
the most common cause of bacteremia was a UTI. P. 
rettgeri and P. stuartii were the most common species. 
Almost all of the patients had urinary catheters. On the 
other hand, P. alcalifaciens and P. rettgeri have been sug-
gested as a cause of diarrhea [11-13]. One patient with P. 
rettgeri bacteremia had gastroenteritis in this study.
The mortality rate for Providencia bacteremia is differ-
ent according to various studies. In the reviews of Pren-
tice and Robinson [3] and Woods and Watanakunakorn 
[4], the mortality rate for Providencia bacteremia was 33 
and 24%, respectively. On the other hand, four out of 
eight patients (50%) with Providencia bacteremia died of 
the infection in a review by Kim et al. [5]. In this study, 
the mortality rate of bacteremia was 29%. We presume 
that this is due to differences in the sources of bactere-
mia included in the studies. In our study, primary bac-
teremia had the highest mortality rate (75%), while the 
mortality rate of UTI-associated bacteremia was 20%. In 
previous studies with lower mortality rates [3,4], a UTI 
was the source in 100% and 71% of cases, respectively. In 
a study by Kim et al. [5], primary bacteremia was the most 
common source of bacteremia; only two UTI-associated 
cases were included. Therefore, the mortality associat-
ed with Providencia bacteremia depends on the source 
of bacteremia, and the mortality rate for UTI-associat-
ed Providencia bacteremia is not high. Not surprisingly, 
the high mortality in patients with primary bacteremia 
and favorable outcome of urosepsis are consistent with 
previous studies of gram-negative bacteremia [14,15]. In 
contrast, all three patients with pneumonia survived. 
The underlying disease severity was significantly high-
er in nonsurvivors. This finding emphasizes that host 
factors may play an important role in the outcome of pa-
tients with Providencia bacteremia.
In our study, cefepime, amikacin, isepacin, imipen-
em, and piperacillin-tazobactam had excellent activity 
against Providencia species. Virtually all Providencia spe-
cies can produce inducible AmpC β-lactamases, and 
many isolates may also produce extended-spectrum 
β-lactamases in nosocomial settings [1,16]. Providencia 
species are intrinsically resistant to polymyxins and tige-
cycline, which are considered last resort antibiotics for 
resistant pathogens [17,18]. The susceptibility to cipro-
floxacin also decreased from 100% to 46% over a 6-year 
period [19]. In a report by Kim et al. [5], 50% of the iso-
lates were resistant to ciprofloxacin, similar to our find-
ings. Plasmid-mediated resistance (e.g., extended-spec-
trum β-lactamases and metallo-β-lactamases) has been 
reported in clinical isolates [16,20,21]. An outbreak of 
carbapenem-resistant P. stuartii due to a non-carbapene-
mase production mechanism was also reported [22]. The 
susceptibility of Providencia isolates should be closely 
monitored, and the treatment regimen should be guid-
ed by the susceptibility results. However, the mortali-
ty cases in our study died before the susceptibility test 
results were available. Limited antimicrobial options 
and the possible rapid progression of sepsis highlight 
the need for early detection in patients with Providencia 
bacteremia. New diagnostic technologies for the rapid 
detection of pathogens in the bloodstream (e.g., poly-
merase chain reaction, microarrays, and matrix-asso-
ciated laser desorption/ionization time-of-flight mass 
spectrometry) are expected to reduce the time to organ-
ism identification. Moreover, effective infection control 
and antibiotic stewardship are emphasized to prevent 
the development of invasive infections and antibiotic 
resistance in Providencia species. In this study, most of 
the cases of Providencia bacteremia had nosocomial in-
fections and urinary catheters. Therefore, urinary cath-
eter infection control measures, including an avoidance 
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of the routine use of urinary catheters, might reduce the 
risk of Providencia bacteremia.
Our study has some limitations. First, this is a cross-sec-
tional study with a small number of patients conduct-
ed at a single university hospital in Korea. Therefore, 
well-designed large-scale studies are warranted. Second, 
a sequence analysis of the Providencia isolates was not 
performed; thus, we cannot exclude the possibility of 
misidentification. Third, more than half of the episodes 
in this study were polymicrobial bacteremia. We cannot 
exclude the effects of co-pathogens on clinical features 
and outcomes.
In summary, in this study, Providencia bacteremia was: 
(1) primarily due to a nosocomial infection occurring 
in elderly patients with cerebrovascular or neurologic 
disease; (2) frequently associated with indwelling uri-
nary catheter use and a UTI; (3) more fatal in cases with 
primary bacteremia and severe underlying disease; and 
(4) frequently associated with polymicrobial infection, 
making the selection of appropriate empirical antibiotic 
therapy difficult.
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